New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 15, 2014
07:48 EDTPRGOPerrigo could be acquired, says RBC Capital
After Globes suggested that Perrigo has hired an investment bank to sell the company. RBC Capital thinks the company has several attributes that could appeal to potential acquirers, including its ability to serve as an inversion vehicle. However, the firm believes that Perrigo could also acquire another company instead. RBC Capital keeps a $160 price target and Outperform rating on the shares.
News For PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent PRGO news | >>
April 21, 2015
16:17 EDTPRGOPerrigo sees CY15 revenue $5.4B-$5.7B
Subscribe for More Information
16:15 EDTPRGOPerrigo sets three-year CAGR goal for 2014-2017 of 5-10%
Subscribe for More Information
16:14 EDTPRGOPerrigo sees CY15 adjusted EPS $7.50-$8.00
Subscribe for More Information
16:12 EDTPRGOPerrigo reports Q3 adjusted EPS $1.85, consensus $1.78
Subscribe for More Information
16:11 EDTPRGOPerrigo board rejects Mylan bid, says offer undervalues company
Subscribe for More Information
16:09 EDTPRGOPerrigo board unanimously rejects unsolicited proposal from Mylan
14:57 EDTPRGOPerrigo puts active on Teva proposal to acquire Mylan
Subscribe for More Information
14:43 EDTPRGOPerrigo set to reject Mylan bid as soon as this week, Reuters says
Subscribe for More Information
14:12 EDTPRGOPerrigo seen rejecting Mylan bid as soon as this week, Reuters says
Subscribe for More Information
13:31 EDTPRGOPerrigo downgraded to Hold from Buy at Stifel
Subscribe for More Information
12:33 EDTPRGOOn The Fly: Top stock stories at midday
Subscribe for More Information
11:57 EDTPRGOAkorn rises, Perrigo slips after Teva makes long-rumored Mylan bid
The shares of drugmaker Akorn (AKRX) are rising after Israeli pharmaceutical company Teva (TEVA) earlier today made a takeover bid for another company in the space, generic drugmaker Mylan (MYL). WHAT'S NEW: Teva announced an $82 per share takeover bid for generic drug maker Mylan earlier today. The latter company said that Teva's takeover offer is a more attractive option for it than acquiring another generic drug maker, Perrigo (PRGO). On April 8, Mylan made a $205 per share takeover offer for Perrigo. Teva's bid comes less than a week after Mylan Chairman Robert Coury said that rumors of potential interest from Teva had been "circulating for some time," but that such a combination was "without sound industrial logic or cultural fit" and would be unlikely to receive antitrust regulatory clearances. ANALYST OPINION: In a note to investors on April 15, RBC Capital analyst Randall Stanicky wrote that Perrigo may have been engaging other companies in talks after Mylan came public with its takeover offer. Stanicky said he saw no clear competing bidder for Perrigo, however, and used a $230 per share takeover while analyzing possible deals. The analyst added that Acorn is well-positioned as a derivative takeover target following Mylan's offer for Perrigo, noting Acorn's strong growth and high tax rate. In a note to investors yesterday, Citigroup said it believed a potential takeover of Mylan by Teva would have to be friendly after its legal due diligence indicated Mylan's poison pill "presents a legitimate roadblock" to a potential hostile takeover. Citi estimated an $80 per share bid for Mylan would be 25%-35% accretive from 2016 onward for Teva while a $90 per share bid would be 20%-30% accretive. The firm added that it believes it is likely that Mylan received resistance from shareholders since the announcement of its proposed acquisition of Perrigo. PRICE ACTION: In late morning trading, Akorn rose 2.2% to $55.85, Perrigo dropped 2.4% to $193.24, Mylan jumped 9.3% to $74.39, and Teva rose 2.1% to $64.64.
10:09 EDTPRGOHigh option volume stocks
Subscribe for More Information
09:22 EDTPRGOOn The Fly: Pre-market Movers
Subscribe for More Information
09:01 EDTPRGOPerrigo drops after Teva calls Mylan offer more attractive alternative
Shares of Perrigo (PRGO) are moving lower after Teva (TEVA) announced a proposal to acquire Mylan (MYL) in a transaction valued at $82.00 per share, consisting of 50% cash and 50% stock. Mylan on April 8 proposed to acquire Perrigo for $205 per share. In its press release this morning, Teva said its proposal "provides Mylan stockholders with a more attractive alternative to Mylan's proposed acquisition of Perrigo." The proposal would provide Mylan stockholders with consideration representing a 37.7% premium to the stock price of Mylan on April 7, it pointed out. Teva added, "We have long respected Mylanís business, and we are confident that Mylanís Board of Directors and stockholders will agree that our proposal represents a significantly more attractive alternative for Mylan and its stockholders than Mylanís proposed acquisition of Perrigo." Citigroup analysts yesterday said they believe any potential takeover of Mylan by Teva would have to be friendly after legal due diligence indicated Mylan's poison pill "presents a legitimate roadblock" to a potential hostile takeover. In pre-market trading, Perrigo is down $2.18 to $195.56 while Mylan is up $5.46 to $73.50. Teva is up $1.66 to $64.95.
08:54 EDTPRGOPerrigo drops 2.2% to $193.74 after Teva proposes to acquire Mylan
Subscribe for More Information
08:52 EDTPRGOTeva CEO says proposal compelling for both Teva, Mylan stockholders
Subscribe for More Information
08:46 EDTPRGOTeva offers to acquire Mylan for $82.00 per share in cash and stock
Teva Pharmaceutical Industries (TEVA) announced a proposal to acquire all of the outstanding shares of Mylan N.V. (MYL) in a transaction valued at $82.00 per Mylan share, with the consideration to be comprised of approximately 50% cash and 50% stock. The Teva cash and stock proposal provides Mylan stockholders with a substantial premium and immediate cash value, as well as significant potential for future value creation through participation in a financially and commercially stronger company. Tevaís proposal also provides Mylan stockholders with a more attractive alternative to Mylanís proposed acquisition of Perrigo Company plc (PRGO), as announced on April 8, 2015, as well as to Mylan on a standalone basis. Tevaís proposal would provide Mylan stockholders with consideration representing a 37.7% premium to the stock price of Mylan on April 7, 2015, which is the last day of trading prior to Mylanís press release regarding its unsolicited proposal for Perrigo, and a 48.3% premium to the unaffected stock price of Mylan on March 10, 2015, which is the last day of trading prior to widespread speculation of a transaction between Teva and Mylan. The proposed combination of Teva and Mylan would create a leading company in the pharmaceutical industry, well positioned to transform the global generics space. The combined company would leverage its significantly more efficient and advanced infrastructure, with enhanced scale, production network, end-to-end product portfolio, commercialization capabilities and geographic reach. With this platform, the combined company would focus on complex technologies and more durable and sustainable products, in combination with robust capabilities in specialty drug development and commercialization. As a result, the combined company would have a unique and differentiated business model addressing significant trends and discontinuities prevailing today among patients and healthcare systems around the world. The combined company would also have an enhanced financial profile, creating the opportunity for rapid deleveraging and the funding of future growth Ė in generics, specialty and the intersection of the two.
08:41 EDTPRGOOptions expected to be active
Options expected to be active: UA TEVA PRGO MYL UTX QCOM VMW HOG CMG IBM VZ
April 20, 2015
06:39 EDTPRGOCiti believes Teva, Mylan deal would have to be friendly
Subscribe for More Information
1 | 2 | 3 | all recent PRGO news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use